Elevated FISH Her-2/neu Amplification in ER Positive,  IHC Her-2 Equivocal Invasive Breast Cancer Patients of  North-East India

Priyanki Baruah; Anupam Sarma; Mouchumee Bhattacharyya; Pallavi Sarma; Biki Chandra Das; Dhrubajyoti Sarma; Monica Tamuly; Abhijit Talukdar; Gaurav Das; Swati Sharma; Amal Chandra Kataki; Mrinal Deka; Subhradip Karmakar; Avdhesh Kumar Rai

doi:10.31557/apjcc.2024.9.4.705-711

Authors

Priyanki Baruah PA Sangma International Medical College and Hospital, Department of Biochemistry, India.
Anupam Sarma Dr B. Borooah Cancer Institute, Department of Oncopathology, India.
Mouchumee Bhattacharyya Dr B. Borooah Cancer Institute, Department of Radiation Oncology, India.
Pallavi Sarma PA Sangma International Medical College and Hospital, Department of Biochemistry, India.
Biki Chandra Das PA Sangma International Medical College and Hospital, Department of Biochemistry, India.
Dhrubajyoti Sarma PA Sangma International Medical College and Hospital, Department of Biochemistry, India.
Monica Tamuly PA Sangma International Medical College and Hospital, Department of Biochemistry, India.
Abhijit Talukdar Dr B. Borooah Cancer Institute, Department of Surgical Oncology, India.
Gaurav Das Dr B. Borooah Cancer Institute, Department of Surgical Oncology, India.
Swati Sharma Dr B. Borooah Cancer Institute, Department of Oncopathology, India.
Amal Chandra Kataki Assam Down Town University, Faculty of Science, Statistics, India.
Mrinal Deka Dr B. Borooah Cancer Institute, A.K. Azad Road, Gopinath Nagar, Guwahati-781016, Assam, INDIA
Subhradip Karmakar All India Institute of Medical Sciences, Department of Biochemistry, New Delhi, India.
Avdhesh Kumar Rai PA Sangma International Medical College and Hospital, Department of Biochemistry, India.

DOI:

https://doi.org/10.31557/apjcc.2024.9.4.705-711

Keywords:

Estrogen Receptor, Fluoresence in-situ hybridization, Immunohistohemistry, ASCO/ CAP 2018

Abstract

Background: Breast cancer management of Her-2 equivocal breast cancer patients requires assessment by fluorescent in situ hybridization (FISH) for Her-2/neu amplification. Assessment of FISH Her-2/neu amplification status in IHC Her-2 equivocal invasive breast cancer patients of North-East India.

Methods: One hundred sixty-two (n=162) IHC Her-2 equivocal (2+) breast cancer patients were analysed by FISH for Her-2/neu amplification using PathVysion Her-2/neu DNA probe kit. The interpretation of FISH Her-2/neu amplification was based on ASCO/CAP 2018 guidelines.

Results: FISH Her-2/neu amplification was detected in 59.26% (n=96) patients and 40.74% (n=66) patients had no amplification. There were 160 female and 2 male patients. ER-positive patients were 68.51% (n=111) and PR-positive were 54.93% (n=89). “ER+/PR+” status was found in 54.93% (n=89) patients whereas “ER-/PR-’’ in 31.48% (n=51) patients. Significant association was observed between histological grade and FISH Her-2/neu amplification (p=0.036). ER-positive patients had also shown significant association with FISH Her-2/neu amplification (p=0.039). ER+/PR+ patients had shown a trend for higher likelihood of FISH Her-2/neu amplification (p=0.053). There were no significant association observed between FISH Her-2/neu amplification with age (p=0.625), lymph node positivity (p=0.642), laterality (p=0.367), histopathology (p=0.226) and PR-positivity (p=0.199).

Conclusion: FISH Her-2/neu amplification in IHC Her-2 equivocal breast cancer patients of North-East India was found to be significantly associated with ER-positive status and histological grade. ER+/PR+ patients have also an enhanced likelihood of FISH Her-2/neu amplification.